E-Mail
IMAGE: Molecular neurochemist Darrell Mousseau is a professor in USask s Department of Psychiatry and head of the Cell Signalling Laboratory. view more
Credit: University of Saskatchewan
Findings from a new study on Alzheimer s disease (AD), led by researchers at the University of Saskatchewan (USask), could eventually help clinicians identify people at highest risk for developing the irreversible, progressive brain disorder and pave the way for treatments that slow or prevent its onset.
The research, published in the journal
Scientific Reports in early January, has demonstrated that a shorter form of the protein peptide believed responsible for causing AD (beta-amyloid 42, or Aβ42) halts the damage-causing mechanism of its longer counterpart.